TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28672073
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (two doses for 12 weeks)
Study: 18922988
Drug: High hemoglobin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hemoglobin target (13.5 to 14.5 g/dl)
Study: 10507244
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg benfotiamin (S-benzoylthiamine-o-monophosphate, BTMP)
Study: 10507244
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg thiamine mononitrate (TN)
Study: 8251730
Drug: Youjiangzhi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youjiangzhi capsule
Study: 3798932
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg i.v. t.i.d.
Study: 3798932
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg i.v. b.i.d.
Study: 30132960
Drug: Curcuminoids nanomicelles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids nanomicelles (80 mg, three times daily, orally) plus mesalamine (3 g/24 hours, orally)
Study: 30132960
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus mesalamine (3 g/24 hours, orally)
Study: 20567009
Drug: Oral bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisphosphonates (90% alendronate, 10% etidronate)
Study: 18519002
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg one hour before surgery, then 200 mg every 12 hours for five days)
Study: 18519002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only PCA morphine)
Study: 12502022
Drug: YKP10A 400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: YKP10A 400-600 mg/day
Study: 12502022
Drug: YKP10A 100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: YKP10A 100-300 mg/day
Study: 12502022
Drug: YKP10A 700-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: YKP10A 700-900 mg/day
Study: 4028514
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol content beer (reduced from 336.3 ml to 64.5 ml ethanol/week)
Study: 29529146
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g milk protein beverage containing 4.2 g leucine (LEU)
Study: 29529146
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g mixed protein (milk and soy) beverage containing 1.3 g leucine (CON)
Study: 27549509
Drug: Thoracic radiotherapy
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily) plus standard chemotherapy (cisplatin/etoposide)
Study: 27549509
Drug: Thoracic radiotherapy
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily) plus standard chemotherapy (cisplatin/etoposide)
Study: 15978764
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (50 mAs)
Study: 15978764
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (100 mAs)
Study: 8566681
Drug: Bismuth subcitrate,
Normalized name: bismuth subcitrate, tetracycline and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subcitrate, metronidazole and amoxicillin (TG) for two weeks
Study: 6248221
Drug: Cefoperazone (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (2.0 gm IV infusion over 30 minutes)
Study: 6248221
Drug: Cefotaxime (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2.0 gm IV infusion over 30 minutes)
Study: 21500992
Drug: Cetrorelix 0.25
Normalized name: cetrorelix 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 0.25 mg/day
Study: 21500992
Drug: Cetrorelix 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 0.125 mg/day
Study: 9683360
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (two daily irradiations of 1.15 Gy up to 80.5 Gy in 7 weeks)
Study: 2654256
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with cat-hair and dander extract (11 patients)
Study: 29845905
Drug: Bedtime milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime milk snack with 10 g protein (BS10)
Study: 29845905
Drug: Bedtime milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime milk snack with 30 g protein (BS30)
Study: 23778157
Drug: Carbamazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (600 mg)
Study: 23778157
Drug: Lacosamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (200 mg)
Study: 23778157
Drug: Lacosamide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (400 mg)
Study: 16631435
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/d for 5 weeks)
Study: 8985764
Drug: Perioperative nasal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative nasal application of mupirocin calcium ointment, started on the day before surgery, continued for 5 days, twice daily
Study: 8985764
Drug: Perioperative nasal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative nasal application of mupirocin calcium ointment
Study: 4053509
Drug: Baroreceptor stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreceptor stimulation and deactivation by injection of phenylephrine and trinitroglycerine
Study: 29931179
Drug: Intramuscular hydroxocobalamin
Normalized name: Hydroxocobalamin
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular hydroxocobalamin injections (2000 µg loading dose, 1000 µg at follow-up) for 6 months
Study: 29931179
Drug: Oral methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylcobalamin (1000 µg daily) for 6 months
Study: 29931179
Drug: Intramuscular hydroxocobalamin
Normalized name: Hydroxocobalamin
DrugBank: Hydroxocobalamin (DB00200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular hydroxocobalamin injections
Study: 29931179
Drug: Oral methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylcobalamin
Study: 27136318
Drug: Carboplatin monotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin monotherapy
Study: 19363162
Drug: Discussion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussion of substance use (smoking, alcohol, drug use)
Study: 19363162
Drug: Discussion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussion of smoking and drug use
Study: 15752943
Drug: Nebivolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (2.5 to 5.0 mg/day)
Study: 15752943
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 to 80 mg/day)
Study: 1758240
Drug: Succinylcholine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.4 mg/kg
Study: 1758240
Drug: Succinylcholine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.6 mg/kg
Study: 1758240
Drug: Succinylcholine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 0.8 mg/kg
Study: 1758240
Drug: Succinylcholine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.2 mg/kg
Study: 6278919
Drug: 475 mg
Normalized name: niacin 475 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 475 mg iodized oil by mouth
Study: 21839625
Drug: Ciclesonide 40
Normalized name: Ciclesonide 400 microgram and formoterol fumarate dihydrate 12 microgram and tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 40 μg
Study: 20082586
Drug: Repaglinide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (2 mg)
Study: 9681667
Drug: Eptastigmine without
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine without food (30 mg)
Study: 9681667
Drug: Eptastigmine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptastigmine with food (30 mg)
Study: 8006396
Drug: 1.5 MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 MU recombinant interferon alpha 2b (Intron) after steroid withdrawal
Study: 2573379
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tertatolol (T) once daily for one year
Study: 2573379
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (T + D)
Study: 798469
Drug: Clopimozide, 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopimozide, 24 mg weekly (Study I)
Study: 798469
Drug: Clopimozide, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopimozide, daily mean dose of 2.5 mg (Study III)
Study: 798469
Drug: Clopimozide (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopimozide (weekly administration)
Study: 29260533
Drug: C+E group
Normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E group (convention + esomeprazole 40 mg/d intravenously for 1 week)
Study: 29260533
Drug: C group
Normalized name: chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C group (convention treatment only)
Study: 19614946
Drug: glulisine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: glulisine monotherapy
Study: 15481762
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 6 g/d
Study: 8513524
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg diluted in 250 ml dextrose 5% administered 30 min before induction of anaesthesia (Group E)
Study: 8513524
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% infusion (Group P)
Study: 28811749
Drug: Cocoa Flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa Flavanols (900 mg CF)
Study: 28811749
Drug: Placebo (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (13 mg CF)
Study: 18458645
Drug: Bilateral oophorectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral oophorectomy with no previous hormone therapy use
Study: 18458645
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) use within 5 years of bilateral oophorectomy
Study: 18458645
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy use
Study: 15315266
Drug: SKI306X 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKI306X 200 mg three times daily
Study: 15315266
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg sustained release once daily
Study: 11751710
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg) - acute administration
Study: 11751710
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg) - prolonged administration
Study: 11751710
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - prolonged administration
Study: 11751710
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg) - prolonged administration in lean subjects
Study: 3738655
Drug: Vincristine sulphate
Normalized name: Vincristine sulphate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulphate bolus of 1.5 mg/m2
Study: 21871635
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate dispersible tablets (5 mg Zn)
Study: 21871635
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate solution (5 mg Zn/5 mL)
Study: 20976374
Drug: Aspirin -
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin - 200 mg/day (Group Aspirin - GA)
Study: 20976374
Drug: Warfarin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin at individually-adjusted doses (Group Warfarin - GW)
Study: 18545068
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg coadministered with simvastatin 20 mg
Study: 15695129
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg (monotherapy)
Study: 18545068
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy group
Study: 7930468
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg bid)
Study: 3339948
Drug: Veralipride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride (200 mg/day for 20 days) + Naloxone (1.6 mg/h for 4 h)
Study: 31205195
Drug: Asenapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (10-20 mg/d)
Study: 16585867
Drug: Preoperative accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative accelerated hyperfractionated radiotherapy with concurrent cisplatin followed immediately by surgery and intraoperative radiotherapy, completed with early postoperative weekly paclitaxel, two additional cisplatin cycles, and concurrent once‐daily radiotherapy beginning on day 28 after surgery
Study: 31494289
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of a brachial plexus biological dose constraint in IMPT plans (cohort B).
Study: 31494289
Drug: IMPT plans
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IMPT plans without BP biological dose constraint (cohort A).
Study: 29258851
Drug: Synthetic granular
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic granular calcium phosphate compound (CPC)
Study: 16622086
Drug: T-Gel 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-Gel 0.1% MD (multidose)
Study: 16622086
Drug: T-Gel 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-Gel 0.1% SDU (single dose unit)
Study: 16622086
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (T-Gel 0.1% MD and T-Gel 0.1% SDU)
Study: 6529776
Drug: Terconazole (R-42470)
Normalized name: Terconazole
DrugBank: Terconazole (DB00251)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terconazole (R-42470) cream 0.4%
Study: 2189989
Drug: Clotrimazole cream
Normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole cream 1%
Study: 31450520
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT), Nordic walking (NW), and therapeutic touch (TT)
Study: 25389256
Drug: Darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 800/100 mg
Study: 23110478
Drug: Topical Negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Negative Pressure (TNP) with dermal substitute
Study: 23110478
Drug: Topical Negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Negative Pressure (TNP) without dermal substitute
Study: 20213205
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care office-based buprenorphine/naloxone treatment (dosage and duration not specified)
Study: 17541206
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) for approximately 12 weeks
Study: 11825814
Drug: Brimonidine, 0.2%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine, 0.2%, twice a day
Study: 2651758
Drug: 1,25(OH)2D3 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 at a dose of 0.25 to 0.5 microgram daily
Study: 1105116
Drug: Atrovent (parasympatholytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrovent (parasympatholytic drug)
Study: 28804985
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Cue Exposure Therapy (CET)
Study: 19203988
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus 2 x 10(8) CFU/day (Low-dose group)
Study: 19203988
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus 6 x 10(8) CFU/day (High-dose group)
Study: 19443680
Drug: Piperacillin/Tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/Tazobactam 4.5 g
Study: 16758382
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g
Study: 10988100
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microgram, twice daily)
Study: 6531660
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg (initial loading dose)
Study: 6531660
Drug: Histamine H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2-receptor antagonists (high doses)
Study: 22124360
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (3700 MBq)
Study: 16571960
Drug: Sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2.0 mg/kg or greater
Study: 11764220
Drug: Rofecoxib (COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (COX-2 specific inhibitor)
Study: 9432788
Drug: Hypooxyradiotherapy (HRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 50% (single dose - 6 Gy; total dose - 30 Gy; 54 isoGy) for stomach cancer
Study: 9432788
Drug: Hypooxyradiotherapy (HRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 25% (single dose - 5 Gy; total dose - 25 Gy; 40 isoGy) for colonic cancer
Study: 9432788
Drug: Hypooxyradiotherapy (HRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative irradiation with a single HRT dose of 10 Gy (28 isoGy) for breast tumors reduced time of irradiation 4 times
Study: 8217066
Drug: complementary drug
Normalized name: 20-mer complementary to Akt mRNA
DrugBank: Archexin (DB05971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: complementary drug treatment for non-responders
Study: 10282583
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (drugs with computer-generated prompts)
Study: 26885697
Drug: AlgaeCal calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: AlgaeCal calcium supplement (AC)
Study: 21989041
Drug: Focused shockwave
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused shockwave therapy
Study: 21989041
Drug: Radial shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shockwave therapy
Study: 21989041
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Focused and Radial shockwave therapy)
Study: 16930211
Drug: Acamprosate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (2 tablets of 333 mg t.i.d.)
Study: 11124307
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination dorzolamide 2% and timolol 0.5% therapy
Study: 11124307
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of a topical beta-blocker and dorzolamide
Study: 25022840
Drug: 17DD-YF vaccine
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17DD-YF vaccine subdose of 587 IU
Study: 25022840
Drug: 17DD-YF vaccine
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17DD-YF vaccine subdose of 3,013 IU
Study: 25022840
Drug: Current dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current dose of 17DD-YF vaccine (27,476 IU)
Study: 15661551
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment (2 years)
Study: 12464864
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral intake of a formula enriched with arginine and n‐3 fatty acids for 5 days before surgery (pre‐op group)
Study: 12464864
Drug: Same preoperative
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same preoperative treatment prolonged after surgery by jejunal infusion (peri‐op group)
Study: 9798803
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg o.d.
Study: 9690720
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg t.d.s.
Study: 9690720
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg o.d.